Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by webpiloton Dec 23, 2011 11:22am
382 Views
Post# 19348676

Merry Christmas

Merry Christmas

First of all I know I post much too often and will try to tame it down a bit in the New Year.  But, in the past few days there has been much written regarding the shrinking of the brain in early stage Alzheimer's as evidenced by MRI studies, if you are interested you can Google it and articles will show up.  These studies revolve around the cortex, and the hippocampus is closely related to the cerebral cortex.  I don't want to post hyperlinks to the articles as Stockhouse won't appreciate it.  What is interesting as far as Vivimind is concerned is that it reduces the atrophy of the hippocampus by 68%, exactly addressing the problems that these studies are talking about.  Also, the new version of Vivimind, NRM 8499 now in the beginning stages of clinical trials will stop this atrophy by 100% or so it has be written.  Vivimind is now available in Canada of course and is already in other parts of the world. Bellus also has products that others don't even come close to.  All this is now available for .04 per share, a nice Christmas gift indeed.

 

Bullboard Posts